# Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

> **NCT06238167** · PHASE2 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** S-1 therapy
- **DRUG:** low dose SOX therapy

## Key facts

- **NCT ID:** NCT06238167
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06238167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06238167, "Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06238167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*